Oramed Pharmaceuticals
ORMP
59 hedge funds and large institutions have $15.2M invested in Oramed Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 2 closing their positions.
440% more call options, than puts
Call options by funds: $54K | Put options by funds: $10K
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
16% more funds holding
Funds holding: 51 → 59 (+8)
1.62% more ownership
Funds ownership: 12.99% → 14.6% (+1.6%)
1% less capital invested
Capital invested by funds: $15.4M → $15.2M (-$115K)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.2M |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$762K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$321K |
| 4 |
Renaissance Technologies
New York
|
+$258K |
| 5 |
Millennium Management
New York
|
+$46.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$520K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$270K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$209K |
| 4 |
D.E. Shaw & Co
New York
|
-$75.9K |
| 5 |
Jane Street
New York
|
-$72.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CLOS
51
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $2.25K | +$2.08K | +875 | New |
|
|
IA
52
IFP Advisors
Tampa,
Florida
| $1.28K | – | – | – |
|
53
Russell Investments Group
London,
United Kingdom
| $643 | +$594 | +250 | New |
|
|
BCMLT
54
Beacon Capital Management LLC (Tennessee)
Franklin,
Tennessee
| $563 | – | – | – |
|
|
MG
55
Mather Group
Chicago,
Illinois
| $292 | +$238 | +100 | New |
|
|
56
Qube Research & Technologies (QRT)
London,
United Kingdom
| $275 | -$209K | -88,089 | -100% |
|
|
GRP
57
Global Retirement Partners
San Rafael,
California
| $257 | – | – | – |
|
|
IC
58
Innealta Capital
Austin,
Texas
| $33 | +$31 | +13 | New |
|
|
NFSG
59
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$1.92K | -657 | Closed |
|
|
TSWM
60
Tyler-Stone Wealth Management
Beachwood,
Ohio
| – | -$876 | -300 | Closed |
|
61
Simplex Trading
Chicago,
Illinois
| – | +$178 | +75 | New |
|
ORMP Hedge Fund Activity: Q2 2024 in Review
59 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2024, worth a combined $15.2M — down 0.75% from $15.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ORMP positions and 2 closed out — a net gain of 8 holders — while 13 added to existing stakes and 14 trimmed.
The largest buyer was BML Capital Management, adding an estimated $1.2M. The largest seller was Susquehanna International Group, cutting an estimated $520K.
- 59 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2024, up from 51 in Q1 2024.
- Funds reported $15.2M of Oramed Pharmaceuticals stock for Q2 2024, down 0.75% quarter-over-quarter.
- 10 funds opened new Oramed Pharmaceuticals positions in Q2 2024 and 2 closed out, a net change of +8 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2024 was BML Capital Management, an estimated $1.2M added.
- The largest Oramed Pharmaceuticals seller in Q2 2024 was Susquehanna International Group, an estimated $520K sold.
Based on aggregated 13F filings for Q2 2024.